Nakamura Shigeki, Kohno Shigeru
Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Science.
Nihon Rinsho. 2012 Apr;70(4):568-73.
The necessity of newly anti-influenza agents is increasing rapidly after the prevalence of pandemic influenza A (H1N1) 2009. In addition to the existing anti-influenza drugs, novel neuraminidase inhibitors such as peramivir (a first intravenous anti-influenza agent) and laninamivir (long acting inhaled anti-influenza agent) can be available. Moreover favipiravir, which shows a novel anti-influenza mechanism acting as RNA polymerase inhibitor, has been developing. These drugs are expected to improve the prognosis of severe cases caused by not only seasonal influenza but pandemic influenza A (H1N1) 2009 virus and H5N1 avian influenza, and also treat oseltamivir-resistant influenza effectively.
在2009年甲型H1N1大流行性流感流行之后，新型抗流感药物的需求迅速增加。除了现有的抗流感药物外，新型神经氨酸酶抑制剂如帕拉米韦（首个静脉注射用抗流感药物）和拉尼米韦（长效吸入性抗流感药物）也已上市。此外，作为RNA聚合酶抑制剂具有新型抗流感机制的法匹拉韦也在研发中。这些药物有望改善不仅由季节性流感，而且由2009年甲型H1N1大流行性流感病毒和H5N1禽流感引起的重症病例的预后，并且能有效治疗对奥司他韦耐药的流感。
